C12N 2710/24132
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2710/24132 (Use of virus as therapeutic agent, other than vaccine) appears on 148 US grants and 278 published applications in this corpus.
Search patents in C12N- Granted patents
- 148
- Published applications
- 278
- Assignees
- 91
- Inventors
- 354
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 2 |
| 2002 | 0 | 3 |
| 2003 | 4 | 3 |
| 2004 | 1 | 2 |
| 2005 | 1 | 3 |
| 2006 | 0 | 3 |
| 2007 | 3 | 8 |
| 2008 | 0 | 4 |
| 2009 | 3 | 11 |
| 2010 | 4 | 7 |
| 2011 | 5 | 8 |
| 2012 | 4 | 8 |
| 2013 | 5 | 8 |
| 2014 | 8 | 7 |
| 2015 | 7 | 7 |
| 2016 | 3 | 8 |
| 2017 | 5 | 7 |
| 2018 | 5 | 14 |
| 2019 | 8 | 22 |
| 2020 | 12 | 27 |
| 2021 | 8 | 15 |
| 2022 | 13 | 37 |
| 2023 | 9 | 19 |
| 2024 | 7 | 16 |
| 2025 | 13 | 14 |
| 2026 | 11 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic vaccinia virus21 Jul 2026US 12,686,856 B2KM Biologics Co., Ltd.
- Oncolytic virus therapy2 Jun 2026US 12,642,832 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Oncolytic vaccinia virus26 May 2026US 12,637,663 B2KM Biologics Co., Ltd.
- Combination of oncolytic virus with immune checkpoint modulators12 May 2026US 12,622,937 B2Institut Gustave Roussy
- IL-36 cytokine expressing oncolytic viruses for treating cancer28 Apr 2026US 12,611,444 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Tumor neoantigen vaccine system specifically marking heterologous protein, and use thereof8 Oct 2026US 2026/0306620 A1China Pharmaceutical University
- Nucleic Acids Encoding Soluble PD-1 and IL-12 and Uses Thereof13 Aug 2026US 2026/0234662 A1KaliVir Immunotherapeutics, Inc.
- Nucleic Acids Encoding TGF-Beta Inhibitor and IL-12 and Uses Thereof13 Aug 2026US 2026/0234667 A1KaliVir Immunotherapeutics, Inc.
- Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy6 Aug 2026US 2026/0226506 A1Genvira Biosciences, Inc.
- Il-36 cytokine expressing oncolytic viruses for treating cancer30 Jul 2026US 2026/0216291 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
Most cited
By later US patents
- Microorganisms for therapy104US 7,588,767 B2Genelux Corporation · 2009
- Microorganisms for therapy98US 7,754,221 B2Genelux Corporation · 2010
- Microorganisms for therapy85US 7,588,771 B2Genelux Corporation · 2009
- Microorganisms for therapy77US 7,662,398 B2Genelux Corporation · 2010
- Microorganisms for therapy58US 8,021,662 B2Genelux Corporation · 2011